Tag: GlobeNewswire

In accordance with section 7(3) of the Consortium Agreement, an additional General Meeting of Øresundsbro Konsortiet I/S is hereby scheduled to be held by Capsulam on

21^st October 2026.

The agenda is as follows:

1.              Election of the chairman and election of the minutes and presentation of a list of persons entitled to vote.

2.              On the recommendation of the Board of Directors, it is proposed to decide on the payment of an extraordinary dividend of DKK 4.526 mio. to the owners.

Copenhagen, 7 October 2026. 

        

Company Announcement No 56/2026	Peberlyk 4 6200 Aabenraa Denmark Tel +45 74 37 37 37 AL Sydbank A/S CVR No DK 12626509, Aabenraa al-sydbank.com
7 October 2026

Transactions with shares in AL Sydbank by managers and closely associated persons

Under Article 19 of the Market Abuse Regulation AL Sydbank makes public transactions with shares in the Bank conducted by managers and persons closely associated with them.

Reference is made to the attached tables showing detailed information about the transactions.

Yours sincerely

AL Sydbank A/S

Attachments

• Mark Luscombe – UK
• Jørn Adam Møller – UK
• Stig Westergaard – UK

        

Company Announcement No 56/2026	Peberlyk 4 6200 Aabenraa Denmark Tel +45 74 37 37 37 AL Sydbank A/S CVR No DK 12626509, Aabenraa al-sydbank.com
7 October 2026

Transactions with shares in AL Sydbank by managers and closely associated persons

Under Article 19 of the Market Abuse Regulation AL Sydbank makes public transactions with shares in the Bank conducted by managers and persons closely associated with them.

Reference is made to the attached tables showing detailed information about the transactions.

Yours sincerely

AL Sydbank A/S

Attachments

• Mark Luscombe – UK
• Jørn Adam Møller – UK
• Stig Westergaard – UK

        

Company Announcement No 56/2026	Peberlyk 4 6200 Aabenraa Denmark Tel +45 74 37 37 37 AL Sydbank A/S CVR No DK 12626509, Aabenraa al-sydbank.com
7 October 2026

Transactions with shares in AL Sydbank by managers and closely associated persons

Under Article 19 of the Market Abuse Regulation AL Sydbank makes public transactions with shares in the Bank conducted by managers and persons closely associated with them.

Reference is made to the attached tables showing detailed information about the transactions.

Yours sincerely

AL Sydbank A/S

Attachments

• Mark Luscombe – UK
• Jørn Adam Møller – UK
• Stig Westergaard – UK

NNIT A/S has noticed certain rumours in the market and confirms that it is exploring to potentially divest its subsidiary SCALES A/S. Nordea Corporate Finance has been appointed to assist in that process.

The process is at a very early stage and there can be no certainty as to the outcome. Further announcements will be made if and when deemed necessary or appropriate.

For more information, please contact:

Investor Relations	Media Relations
Carsten Ringius                                                                                     EVP & CFO Tel: +45 3077 8888 carr@nnit.com	Thomas Stensbøl Press & Communications Manager Tel: +45 3077 8800 tmts@nnit.com

ABOUT NNIT
NNIT is a leading provider of IT solutions to life sciences internationally, and to the public and private sectors in Denmark.

We focus on high complexity industries and thrive in environments where regulatory demands and complexity are high.

We advise on and build sustainable digital solutions that work for the patients, citizens, employees, end users or customers.

We strive to build unmatched excellence in the industries we serve, and we use our domain expertise to represent a business first approach – strongly supported by a selection of partner technologies, but always driven by business needs rather than technology.

NNIT consists of group company NNIT A/S and subsidiaries, including SCALES. Together, these companies employ around 1,500 people in Europe, Asia and USA.

Attachment

• Company announcement_7Oct26

INVL Sustainable Timberland and Farmland Fund II, a fund investing in EU countries in Central and Eastern Europe and whose asset portfolio is managed by INVL, the leading alternative asset manager in the Baltics, has successfully completed the sale of more than 2,600 hectares of forests in Latvia.

“This transaction is a further confirmation that sustainably managed forest creates real, market-recognised value. Throughout the holding period, we managed this portfolio in line with international sustainable forestry standards. Having now successfully concluded this investment cycle, we plan to reinvest the proceeds into other forest and agricultural land plots,” says Martynas Samulionis, partner of the fund.

The forest portfolio sold was owned by the fund-managed Latvian companies “Zemvalde Forest” and “Zemvalde Agro”. The plots sold by the fund were located mostly in the Vidzeme and Latgale regions. The buyer is a Latvian-registered company owned by Danish investors.

The fund manages 21 thousand hectares of forest and agricultural land in the Baltics and Romania. The fund raised EUR 98 million from investors.

Karl Danielsson Farm & Forest represented INVL in the sale of its Latvian forest portfolio, managing the sales process and supporting the transaction through to completion.

About INVL Sustainable Timberland and Farmland Fund II
Under its strategy, the fund invests in sustainably developed forests and farmland in Central and Eastern European countries in the EU that offer attractive investment returns and a stable regulatory environment. The fund’s activities are guided by international sustainable management practices that create value not only for investors, but also for the environment and society. The alternative investment fund manager of INVL Sustainable Timberland and Farmland Fund II is FundRock LIS S.A., which is a Luxembourg based and AIFMD licensed management company, however, the fund’s asset portfolio is managed by INVL Asset Management, the leading alternative asset management company in the Baltics. It is administered by the Apex Group, one of Europe’s largest providers of fund services.

About INVL Asset Management (INVL)
INVL Asset Management is the leading Baltic alternative asset manager. We strive to deliver superior risk-adjusted returns to our investors while positively impacting our region’s economic development. We are part of the Invalda INVL group with a track record spanning over 30 years. Our group manages or have under supervision more than EUR 2 billion of assets across multiple asset classes including private equity, forests and agricultural land, renewable energy, real estate as well as private debt. Our scope of activities also includes family office services in Lithuania, Latvia and Estonia, management of pension funds in Latvia, and investments in global third-party funds. Further information www.invl.com/en/. 

Further information:
Martynas Samulionis
Managing Partner of the INVL Sustainable Forest and Agricultural Land Fund II
E-mail martynas.samulionis@invl.com

Aspo Plc Stock Exchange Release October 7, 2026 at 9.30 EET

Proposals to the Extraordinary General Meeting of Aspo Plc: Composition of the future Boards of Directors of ESL Shipping Group Plc and Telko Group Plc (currently Aspo Plc)

Aspo Plc announced on 3 August 2026 the approval of the demerger plan concerning the partial demerger of the company. The partial demerger will be resolved upon at the Extraordinary General Meeting to be held on 7 December 2026. Aspo Plc is intended to be renamed Telko Group Plc.

After the possible partial demerger, Heikki Westerlund, Chair of the Board of Directors of Aspo, will step down from the Board. “Over the past five years, I have had the privilege of serving as Chair of the Board during a period of significant transformation. Our success has been built on a good dialogue with our owners, for which I am grateful. The Board, management and Aspo’s employees have delivered outstanding work under challenging circumstances, and it has been an honour to be part of this team. With ESL Shipping and Telko entering their next phase following the demerger, this is a natural time for me to step down from the Board,” says Heikki Westerlund, Chair of the Board, Aspo.

The proposals concerning the composition of the Boards of Directors of both companies will be included in the notice to the Extraordinary General Meeting to be published at a later date.

Aspo Plc / Telko Group Plc: Proposal on the composition of the future Board of Directors

Aspo Plc’s Shareholders’ Nomination Board presents the following proposals to the Extraordinary General Meeting to be held on 7 December 2026.

The Shareholders’ Nomination Board proposes that the Board of Directors of Aspo Plc / Telko Group Plc consist of five members.

The Shareholders’ Nomination Board proposes that Tapio Kolunsarka, Patricia Allam, Annika Ekman, Mikael Laine and Tatu Vehmas be elected as members of the Board of Directors. All proposed persons are currently members of the Board of Directors of Aspo Plc.

The proposed Board members have all given their consent to being elected. The Board of Directors will elect the Chair and may elect a Vice Chair from among its members. The proposed persons have informed the company that, if elected, they will elect Tapio Kolunsarka as Chair of the Board.

Should any of the candidates proposed by the Nomination Board not be available for election, the proposed number of Board members shall be decreased accordingly and the remaining available candidates are proposed to be elected in accordance with the proposal by the Nomination Board.

The proposed Board members are independent of the company and its significant shareholders, with the exception of Patricia Allam and Tatu Vehmas, who are not considered independent of the significant shareholders of the company and Mikael Laine, who is not considered independent of the company. Patricia Allam and Tatu Vehmas are not considered independent of the significant shareholders due to their family relationships. Mikael Laine has been assessed not to be independent of the company based on an overall evaluation, taking into account that he has been a member of the Board of Directors of Aspo Plc for a period of more than ten (10) consecutive years.

The Shareholders’ Nomination Board proposes that the Board of Directors of Aspo Plc / Telko Group Plc commence its term on the later of January 1, 2027, or the effective date of the demerger. The proposals are conditional upon the completion of the demerger.

With regard to the procedure for the selection of the members of the Board of Directors, the Shareholders’ Nomination Board recommends that the shareholders give their view on the proposal as a whole at the General Meeting. The Shareholders’ Nomination Board has estimated that in addition to the qualifications of the individual candidates for the Board of Directors, the proposed Board of Directors as a whole provides excellent competence and experience for the company and that the composition of the Board of Directors also meets other requirements set for a listed company by the Corporate Governance Code.

ESL Shipping Group Plc: Proposal on the composition of the future Board of Directors

The Board of Directors of Aspo Plc presents the following proposals to the Extraordinary General Meeting to be held on 7 December 2026.

The Board of Directors of Aspo Plc proposes that the Board of Directors of ESL Shipping Group Plc, to be incorporated in the demerger, consist of four members. Rolf Jansson, Mikael Laine, Andreas Remmer and Kaarina Ståhlberg are proposed to be elected as members of the Board of Directors. Kaarina Ståhlberg and Mikael Laine are currently members of the Board of Directors of Aspo Plc.

The proposed Board members have all given their consent to being elected. Rolf Jansson is proposed as Chair of the Board of Directors. The Board of Directors may elect a Vice Chair from among its members.

The term of the members of the Board of Directors shall commence on the effective date of the demerger and shall expire at the end of the first Annual General Meeting of ESL Shipping Group Plc following the effective date.

The proposed Board members are independent of the company and its significant shareholders, with the exception of Rolf Jansson and Mikael Laine, who are not considered independent of the company. Rolf Jansson currently acts as the CEO of Aspo Plc. Mikael Laine has been assessed not to be independent of the company based on an overall evaluation, taking into account that he has been a member of the Board of Directors of Aspo Plc for a period of more than ten (10) consecutive years.

Proposal for the remuneration of the Boards of Directors

The Shareholders’ Nomination Board proposes that the following monthly fees be paid to the members of the Boards of Directors of Aspo Plc / Telko Group Plc and ESL Shipping Group Plc:

– Members of the Board of Directors: EUR 3,000 per month
– Chair of the Board of Directors: EUR 6,000 per month

The Shareholders’ Nomination Board proposes that the members of the possible Board committees of both companies be paid a meeting fee of EUR 500 per committee meeting or a meeting fee of EUR 1,000 when the meeting requires travel outside the member’s country of residence. The proposed fee for the committee Chair is EUR 1,200 per committee meeting.

The proposed Board remuneration is conditional upon the completion of the demerger.

For Aspo Plc / Telko Group Plc, the proposed Board remuneration will take effect when the new Board of Directors commences its term.

For ESL Shipping Group Plc, the proposed Board remuneration will take effect from the later of 1 January 2027 or the effective date of the demerger.

Composition of the Shareholders’ Nomination Board

The Nomination Board of Aspo Plc’s shareholders consists of the representatives of the four largest shareholders. The following representatives of the largest shareholders were members of the Nomination Board which prepared proposals for the Extraordinary General Meeting 2026: Roberto Lencioni, Chairman (Vehmas family, including AEV Capital Holding Oy); Gustav Nyberg (Nyberg family, including Oy Havsudden Ab); Pekka Pajamo, (Varma Mutual Pension Insurance Company); and Karoliina Lindroos (Ilmarinen Mutual Pension Insurance Company). In addition, Heikki Westerlund, Chair of Aspo Plc’s Board of Directors, has acted as an expert member of the Nomination Board.

Aspo Plc 

For further information, please contact:

Roberto Lencioni, Chair of the Shareholders’ Nomination Board, roberto.lencioni@gard.no

Heikki Westerlund, Chair of the Board of Directors, heikki@heiwes.com

More information on the planned partial demerger is available at aspo.com/demerger.

DISTRIBUTION:
Nasdaq Helsinki
Key media
www.aspo.com

^{Aspo creates value by owning and developing business operations sustainably and in the long term. Aspo’s businesses – ESL Shipping and Telko – enable future-proof, sustainable choices for customers in various industries. Established in 1929, today we are together about 650 experts on land and at sea. While the Nordic region is our core market, we serve our customers with world-class solutions in 18 countries around Europe and parts of Asia.}

^{Aspo is listed on Nasdaq Helsinki and is headquartered in Finland.}

^{Aspo – Sustainable value creation}

Please find herewith the press release.

Attachment

• p261007E – Publication of a transparency notification

Licaminlimab genotype-based precision medicine approach for TNFR1-mediated dry eye disease in PREDICT-1 registrational symptoms trial on track for topline readout around year-end

ZUG, Switzerland, October 7, 2026 — Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced that Riad Sherif, M.D., Chief Executive Officer of Oculis, will present at Eyecelerator @ AAO 2026 on October 8, 2026, and that the Company will sponsor the Neuro-Ophthalmology Subspecialty Day at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting on October 9, 2026, in New Orleans, Louisiana. 

At Eyecelerator @ AAO 2026, Dr. Sherif will present Licaminlimab, a novel topical anti-TNFα candidate being developed with a genotype-based precision medicine approach for TNFR1-mediated dry eye disease, in the PREDICT-1 registrational symptoms trial on track for topline readout around year-end.

Oculis will also partner with the Neuro-Ophthalmology Subspecialty Day, reflecting the Company’s commitment to advancing neuro-ophthalmology through scientific exchange, education, and collaboration with experts in research, clinical practice, and emerging technologies to improve care for patients with neuro-ophthalmic diseases. 

Riad Sherif, M.D., Chief Executive Officer of Oculis, said: “AAO provides a valuable opportunity to engage with the broader ophthalmology and neuro-ophthalmology communities and discuss how innovation can address persistent unmet needs in both fields. The upcoming topline results from PREDICT-1 have the potential to further advance our aim of bringing precision medicine to TNFR1-mediated dry eye disease, while the continued progress of Privosegtor reflects our commitment to transforming outcomes for patients facing neuro-ophthalmic diseases. Together, these programs illustrate Oculis’ strategy of pursuing highly differentiated therapies with the potential to redefine standards of care.”

Details of Oculis’ presentation at Eyecelerator @ AAO 2026 are as follows: 

Session: Anterior segment showcase
Date / Time: October 8, 1:24 PM CDT
Room: 243-245
Presenter: Riad Sherif, M.D., Chief Executive Officer

– Ends –

About Licaminlimab 

Licaminlimab is an anti-TNFα eye drop candidate being developed with a single chain antibody fragment (scFv) technology specifically developed to treat ocular inflammatory diseases. The dual anti-inflammatory and anti-necrotic mechanism of action of TNFα inhibition is well established in inflammatory disorders, where systemic use of TNFα inhibitors has led to marked improvements in disease management and treatment outcomes. In Phase 2 trials, Licaminlimab has shown a positive treatment effect on both the signs and symptoms of dry eye disease and has been well tolerated. In addition, a genetic biomarker has been identified that showed a more pronounced treatment effect with Licaminlimab in patients with a specific TNFR1 genotype. If approved, Licaminlimab has the potential to transform the treatment paradigm with a precision medicine approach. 

Licaminlimab is an investigational drug in a registrational trial and has not received regulatory approval for commercial use in any country. 

About Privosegtor 

Privosegtor, a novel peptoid small-molecule candidate that crosses the blood-brain and retinal barriers, has the potential to become the first neuroprotective therapy for optic neuritis (ON) and other neuro-ophthalmic and neuro-axonal diseases. Positive results from the ACUITY Phase 2 trial showed Privosegtor’s neuroprotective potential, as evidenced by improvements in visual function, corroborated by anatomical preservation of the retina, including GCIPL and RNFL layers, and reduced neurofilament levels in the blood after an acute episode of optic neuritis. Consistent results were observed in animal models of glaucoma, optic neuritis and multiple sclerosis, where Privosegtor preserved retinal ganglion cells and was associated with improvements in mobility in the multiple sclerosis model. 

Privosegtor has received Breakthrough Therapy designation from the U.S. Food and Drug Administration and Priority Medicines (PRIME) designation from the European Medicines Agency, as well as Orphan Drug designation from both agencies for ON. Privosegtor is currently being evaluated in Oculis’ PIONEER (Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research) program, which includes two registrational trials in ON and one registrational trial in non-arteritic anterior ischemic optic neuropathy. 

Privosegtor is an investigational drug and has not received regulatory approval for commercial use in any country. 

About Oculis 

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology. Oculis’ highly differentiated late-stage clinical pipeline focuses on two core product candidates. Privosegtor is a breakthrough neuroprotective candidate in the PIONEER program, which consists of studies intended to support registration plans for treatment of optic neuropathies, including optic neuritis and non-arteritic anterior ischemic optic neuropathy. Privosegtor also has potential to be developed for additional indications in other neuro-ophthalmic and neuro-axonal diseases. Licaminlimab is a novel, topical anti-TNFα in a registrational trial and is being developed with a genotype-based approach for treating patients with dry eye disease. Headquartered in Switzerland with operations in the U.S., Iceland and Switzerland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors. 

For more information, please visit: www.oculis.com 

Contacts 

Oculis Contact 
Ms. Sylvia Cheung, CFO 
sylvia.cheung@oculis.com 

Investor Relations 
LifeSci Advisors 
Corey Davis, Ph.D. 
cdavis@lifesciadvisors.com 

Media Relations 
ICR Healthcare 
Amber Fennell / David Daley / Sean Leous 
oculis@icrhealthcare.com 

Cautionary Statement Regarding Forward-Looking Statements 

This press release contains forward-looking statements and information. For example, statements regarding the potential benefits of the Company’s product candidates, including the potential for Privosegtor to become the first neuroprotective therapy for optic neuritis and other neuro-ophthalmic and neuro-axonal diseases and the potential for Licaminlimab to transform the treatment paradigm in dry eye disease with a precision medicine approach; the initiation, enrollment, timing, progress and results of current and future clinical trials; Oculis’ research and development programs, regulatory and business strategy; Oculis’ future development plans; the timing or likelihood of regulatory filings and approvals; and statements about market opportunity, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and subject to risks, variability and contingencies, many of which are beyond Oculis’ control. Results from prior clinical trials may not be replicated in later clinical trials. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those expected and/or expressed or implied by such forward-looking statements, including those set forth in the Risk Factors section of Oculis’ annual report on Form 20-F and any other documents filed with the U.S. Securities and Exchange Commission. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

ORION CORPORATION
STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE
7 OCTOBER 2026 at 9.00 EEST
        

125,000 Orion Corporation A shares converted into B shares

In accordance with Section 3 of the Articles of Association of Orion Corporation, 125,000 A shares have been converted into 125,000 B shares. The conversion has been entered into the Trade Register on 7 October 2026.

The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 31,146,179 A shares and 109,988,099 B shares. The number of votes of the company’s shares is after the conversion 732,911,679.

Orion Corporation

Liisa Hurme President and CEO

Mikko Kemppainen General Counsel

Contact person:
Tuukka Hirvonen, Head of Investor Relations, tel. +358 10 426 2721
                                                 

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orionpharma.com

Orion Pharma is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals as well as active pharmaceutical ingredients, combining our trusted expertise with continuous innovation. We have an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by us are used to treat cancer, respiratory diseases and neurological diseases, among others. In 2025 our net sales amounted to EUR 1,890 million, and we employ about 4,000 professionals worldwide, dedicated to building well-being.